This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients.
In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The EUnetHTA Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO, an overview of available evidence and Evidence gaps of REGN-COV2 in the target patient populations with relevant comparators.
For any questions regarding the Rapid Collaborative Review, please contact email@example.com.
Please find the review here: